301 related articles for article (PubMed ID: 26517178)
1. Application of flow cytometry for myelodysplastic syndromes: Pitfalls and technical considerations.
Alhan C; Westers TM; Cremers EM; Cali C; Ossenkoppele GJ; van de Loosdrecht AA
Cytometry B Clin Cytom; 2016 Jul; 90(4):358-67. PubMed ID: 26517178
[TBL] [Abstract][Full Text] [Related]
2. The role of flow cytometric immunophenotyping in myelodysplastic syndromes.
Pagnucco G; Giambanco C; Gervasi F
Ann N Y Acad Sci; 2006 Nov; 1089():383-94. PubMed ID: 17261782
[TBL] [Abstract][Full Text] [Related]
3. Flow cytometry immunophenotyping for the evaluation of bone marrow dysplasia.
Della Porta MG; Lanza F; Del Vecchio L;
Cytometry B Clin Cytom; 2011; 80(4):201-11. PubMed ID: 21674774
[TBL] [Abstract][Full Text] [Related]
4. Bone marrow immunophenotyping by flow cytometry in refractory cytopenia of childhood.
Aalbers AM; van den Heuvel-Eibrink MM; Baumann I; Dworzak M; Hasle H; Locatelli F; De Moerloose B; Schmugge M; Mejstrikova E; Nováková M; Zecca M; Zwaan CM; Te Marvelde JG; Langerak AW; van Dongen JJ; Pieters R; Niemeyer CM; van der Velden VH
Haematologica; 2015 Mar; 100(3):315-23. PubMed ID: 25425683
[TBL] [Abstract][Full Text] [Related]
5. [The role of bone marrow cells immunophenotypic study by flow cytometry in diagnosing myelodysplastic syndrome].
Czyz A; Dworacki G; Komarnicki M
Postepy Hig Med Dosw (Online); 2008 Jul; 62():354-63. PubMed ID: 18688206
[TBL] [Abstract][Full Text] [Related]
6. Multiparameter flow cytometry is instrumental to distinguish myelodysplastic syndromes from non-neoplastic cytopenias.
Cremers EMP; Westers TM; Alhan C; Cali C; Wondergem MJ; Poddighe PJ; Ossenkoppele GJ; van de Loosdrecht AA
Eur J Cancer; 2016 Feb; 54():49-56. PubMed ID: 26720403
[TBL] [Abstract][Full Text] [Related]
7. A multiparametric flow cytometry immunophenotypic scoring system for the diagnosis and prognosis of myelodysplastic syndromes.
Huang J; Lai P; Zhou M; Weng J; Lu Z; Du X
Clin Lab; 2012; 58(11-12):1241-51. PubMed ID: 23289195
[TBL] [Abstract][Full Text] [Related]
8. [Role of flow cytometric immunophenotyping in diagnosis of myelodysplastic syndromes--review].
Zhang Y; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Dec; 16(6):1477-81. PubMed ID: 19099668
[TBL] [Abstract][Full Text] [Related]
9. High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes.
Alhan C; Westers TM; Cremers EM; Cali C; Witte BI; Ossenkoppele GJ; van de Loosdrecht AA
Br J Haematol; 2014 Oct; 167(1):100-9. PubMed ID: 24976502
[TBL] [Abstract][Full Text] [Related]
10. Profiling myelodysplastic syndromes by mass cytometry demonstrates abnormal progenitor cell phenotype and differentiation.
Behbehani GK; Finck R; Samusik N; Sridhar K; Fantl WJ; Greenberg PL; Nolan GP
Cytometry B Clin Cytom; 2020 Mar; 98(2):131-145. PubMed ID: 31917512
[TBL] [Abstract][Full Text] [Related]
11. Screening bone marrow samples for abnormal lymphoid populations and myelodysplasia-related features with one 10-color 14-antibody screening tube.
Rajab A; Porwit A
Cytometry B Clin Cytom; 2015; 88(4):253-60. PubMed ID: 25664445
[TBL] [Abstract][Full Text] [Related]
12. A series of case studies illustrating the role of flow cytometry in the diagnostic work-up of myelodysplastic syndromes.
Westers TM; Saft L; van der Velden VHJ; Te Marvelde JG; Dunlop A; Ireland R; Valent P; Porwit A; Béné MC; van de Loosdrecht AA
Cytometry B Clin Cytom; 2023 Jan; 104(1):87-97. PubMed ID: 35179296
[TBL] [Abstract][Full Text] [Related]
13. The diagnostic and prognostic significance of flow cytometric bone marrow assessment in myelodysplastic syndromes according to the European LeukemiaNet recommendations in single-centre real-life experience.
Majcherek M; Kiernicka-Parulska J; Mierzwa A; Barańska M; Matuszak M; Lewandowski K; Komarnicki M; Czyż A
Scand J Immunol; 2021 Aug; 94(2):e13028. PubMed ID: 33577137
[TBL] [Abstract][Full Text] [Related]
14. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group.
Westers TM; Ireland R; Kern W; Alhan C; Balleisen JS; Bettelheim P; Burbury K; Cullen M; Cutler JA; Della Porta MG; Dräger AM; Feuillard J; Font P; Germing U; Haase D; Johansson U; Kordasti S; Loken MR; Malcovati L; te Marvelde JG; Matarraz S; Milne T; Moshaver B; Mufti GJ; Ogata K; Orfao A; Porwit A; Psarra K; Richards SJ; Subirá D; Tindell V; Vallespi T; Valent P; van der Velden VH; de Witte TM; Wells DA; Zettl F; Béné MC; van de Loosdrecht AA
Leukemia; 2012 Jul; 26(7):1730-41. PubMed ID: 22307178
[TBL] [Abstract][Full Text] [Related]
15. The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system.
Alhan C; Westers TM; Cremers EM; Cali C; Witte BI; Ossenkoppele GJ; van de Loosdrecht AA
Leukemia; 2016 Mar; 30(3):658-65. PubMed ID: 26503643
[TBL] [Abstract][Full Text] [Related]
16. Multicenter comparison of CD34+ myeloid cell count by flow cytometry in low-risk myelodysplastic syndrome. Is it feasible?
Font P; Subirá D; Matarraz S; Benavente C; Cedena MT; Morado M; Pérez Corral A; Bellón JM; Díez-Martín JL
Cytometry B Clin Cytom; 2018 May; 94(3):527-535. PubMed ID: 28618451
[TBL] [Abstract][Full Text] [Related]
17. Role of flow cytometry in diagnostics of myelodysplastic syndromes--beyond the WHO 2008 classification.
Porwit A
Semin Diagn Pathol; 2011 Nov; 28(4):273-82. PubMed ID: 22195405
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a Bone Marrow Dysmyelopoiesis Immunophenotypic Index for the Diagnosis and Prognosis of Myelodysplastic Syndromes.
Verigou E; Lampropoulou P; Smyrni N; Kolliopoulou G; Sakellaropoulos G; Starakis I; Zikos P; Solomou E; Symeonidis A; Karakantza M
Cardiovasc Hematol Disord Drug Targets; 2015; 15(2):148-61. PubMed ID: 26126819
[TBL] [Abstract][Full Text] [Related]
19. [Application of flow cytometry in detecting dysplasia of myelodysplastic syndromes].
Li J; He GS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):1069-72. PubMed ID: 23998614
[TBL] [Abstract][Full Text] [Related]
20. Revising flow cytometric mini-panel for diagnosing low-grade myelodysplastic syndromes: Introducing a parameter quantifying CD33 expression on CD34+ cells.
Ogata K; Sei K; Saft L; Kawahara N; Porta MGD; Chapuis N; Yamamoto Y
Leuk Res; 2018 Aug; 71():75-81. PubMed ID: 30025279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
